LT: Liver transplantation; DC: Donor Chimerism; DDLT: Deceased donor liver transplant; HSCT: Hematopoietic stem cell transplantation; TAC: Tacrolimus; CyA: Ciclosporin

Long-term acceptance of transplanted organs without requirement for indefinite immunosuppression remains the ultimate goal of transplant clinicians and scientists [1]. Currently, more than 90% of all liver transplant recipients are treated with the calcineurin inhibitors cyclosporine or tacrolimus [2]. Patients are faced with severe complications of immunosuppressant therapy such as infections, metabolic disturbances, malignancies [3], and drug-specific toxicity such as nephrotoxicity when treated with these inhibitors [4,5].

The incidence of chronic rejection is much lower in liver transplantation cases, compared to other organ grafts [6], and approximately 20% of stable recipients can be weaned off immunossuppresive medication without developing graft rejection.

New recommendations on this subject, included in a meta-analysis study, have shown that randomized trials are needed to evaluate calcineurin inhibitor reduction versus continuation of calcineurin inhibitor treatment; but these randomized trials should only be performed in carefully selected patients [2].

The proposal that microchimerism induces tolerance was first put forward by Starzl et al. [7]. Starzl and Zinkernagel hypothesized that organ engraftment is a form of chimerism-dependent partial tolerance [7-13] and this tolerance can be inferred from the amount of immunosuppression necessary to maintain the stable function and structure of the graft.

Previously we have reported that “Stable, high levels of donor chimerism (DC), in the absence of other major clinical events, may be a marker of transplantation tolerance” [14] in a cohort of fortytwo liver transplant recipients without lowering the amount of immunossuppression. Nonspecific genomic (NK, CD T cell genes), immunophenotypic (CD4+CD25highFOXP3+, T cells), and HLA (soluble HLA-G) signatures also appear to be ready for testing as tolerance predictors in prospective studies [15-18].

It has been demonstrated that donor NK cells may promote engraftment, prevent graft- versus host disease, control infections, and reduce the risk of leukemia relapse in hematopoietic stem cell transplantation (HSCT). It has also been established that NK cell alloreactivity is affected by many determinants, including donor versus recipient KIR ligand compatibility, KIR-HLA receptor ligand mismatch, and the milieu of cytokine such as IL-12 and IL-18 [19-21]. KIR genotype and KIR-HLA-C ligand compatibility play roles in recurrence and progression of hepatitis C [22] and graft rejection [23] in liver transplant recipients.

In the field of hematology, the killer immunoglobulin-like receptor /HLA ligand matching plays a part in T-cell complete DC in hematopoietic stem cell transplantation. And Natural Killer cells can exert a graft vs. tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. We hypothesized that NK function and KIR/ HLA matching could modify DC levels in liver recipients. Taking into account the immunological aspects, we also studied cytokine levels as potential biomarkers to predict acute cellular rejection. We also examined these cytokines in relation to DC and the NK function.

The aim of the study is to develop a predictive model of graft rejection in liver transplant recipients based on DC quantification, NK cell study and cytokine levels (IL1β, IL5, IL7, IL12, IL13, IL17, GCSF, MCP1, MIP1B, IL2, IL4, IL6, IL8, IL10, GMCSF, IFNγ, TNFα) in a cohort of liver recipients and their donors in a prospective study.

Chimerism study

Characteristics of recipients and donors: A total of 80 Deceased Donor Liver Transplant (DDLT) recipients and their respective donors took part initially in this study, but eventually it was conducted with 74 LT recipients. Six LT cases were not studied, non-informative polymorphism between recipient and donor was found in two of them, two patients had died before the first post-transplantation samples were collected, and in two cases, donor samples were not available. All patients underwent transplantation at the General Surgery of the Alimentary Tract and Abdominal Organ Transplantation Department of the 12 de Octubre Hospitals (Madrid, Spain) between October 2008 and January 2011. The study was approved by the Ethical Institutional Review Board of 12 de Octubre Hospital and all patients gave their consent to participate in the study in compliance with the Declaration of Helsinki. The characteristics of patients and immunosuppressive regimen are summarized in Table 1.

Table 1: Liver Transplant Recipient Characteristics in a peripheral chimerism study.

Sample collection and DNA preparation: A total of 792 samples were studied. 156 were pre-transplantation from both donors and recipients; 468 were post-transplantation peripheral blood samples from recipients (from 74 recipients) and 168 were post-transplantation serum samples from recipients (from 25 recipients).

Genotyping and chimerism analysis: Seven insertion-deletion bi-allelic polymorphisms (GSTM, GSTT, SRY, Xq28, FVII, RhD, and rs4399) were detected with Hyb probes, and 14 SNPs (S1a, S1b, S4a, S4b, S5a, S5b, S7a, S7b, S8a, S8b, S9a, S9b, S11a, and S11b) were detected with TM probes. Quantitative real time PCRs and chimerism quantification were performed as described previously by Ayala et al. [14,24,25].

DC was expressed as a percentage of donor DNA in the posttransplant recipient sample in this study.

HLA typing and KIR genotyping, phenotyping, and cytotoxicity

Characteristics of the recipients and donors: A total of 23 LT patients and their respective donors took part in this study. All patients underwent transplantation at the 12 de Octubre Hospital during the period of time already stated above. In these cases ethical issues were completed as well. The characteristics of patients and immunosuppressive regimen are summarized in Table 2.

Table 2: Liver Transplant Recipient Characteristics in a NK cell study.

Sample collection and DNA preparation: KIR phenotype was studied in 10 peripheral blood donor samples, and 11 pretransplantation and 8 post- transplantation peripheral blood recipient samples. The cytotoxicity assay was made in 9 donor samples, and 11 pre-transplantation and 11 post- transplantation recipient samples. KIR genotyping and KIR ligand (HLA-I typing) were studied in 13 donor samples and 23 pre-transplantation and 13 post-transplantation recipient samples.

Antibodies and flow cytometry analysis: The following fluorochrome-labeled monoclonal antibodies (mAbs) against human antigens were obtained from Becton Dickinson (Franklin Lakes, NJ, USA): CD3 PE-Cy7, CD20-PE, CD45-FITC, CD158b1FITC, NKG2DAPC. HLA Lineage-FITC, HLADR-APC-Cy7, CD11c-PECy5, CD45RA-PE-Cy5, CD158 a,h-PE, and CCR7-PE. Fluorochromelabeled mAbs against CD19-PE, CD56-APC were obtained from Beckman Coulter (Fullerton, CA, USA).

NK cell, NK cell subsets, T cell, T cell subsets, B cell, and NKT cell phenotyping was performed on fresh samples of whole blood by multiparametric flow cytometry (Becton Dickinson, FACSCanto II). NK cells were defined as CD3-negative CD56-positive cells. The NK dim cell subset was defined as a moderate expression of CD56 on NK cells, and the NK bright cell subset was defined as a high expression of CD56 on NK cells.

KIR genotyping and KIR ligand (HLA-I typing): Fifteen human KIR genes and two pseudo genes were analyzed by PCR with a KIR typing kit (Miltenyi Biotec, Bergisch Gladbach, Germany). KIR A and B haplotype were performed as described previously by A. Pérez- Martínez et al (BMT 2012) KIR ligand HLA-C allotypes (C1 and C2) and HLA-B allotypes (Bw4) were determined using high-resolution PCR-sequence-based typing.

Cytotoxicity assays: The natural cytotoxicity of NK cells was evaluated as described formerly by Perez-Martinez et al. (BMT 2012) The number of NK cells was calculated by multiplying the lymphocyte counts by the percentage of CD3-CD56+ NK cells.

The equations used to calculate spontaneous and specific cytotoxicity were also previously defined by Perez-Martinez et al. [26].

Luminex assay for cytokine measurement: Recipient pre (n=62) and post (n=109) transplantation serum samples were analyzed by ELISA according to the manufacturer’s instructions: Biorad? 17-plex kit on a Luminex? platform. The selected mediators included Th1 cytokines (IL-2; IL-12p70); Th2 cytokines (IL-4; IL-5; IL-10; IL-13); Th17 cytokines (IL-6; IL-17); growth factors (GM-CSF; GCSF); chemokines (IL-8; MCP-1; MIP-1b), and also IL-7. All samples and standards were run in duplicate. Data analyses of all assays were performed with the Bio-Plex manager software (BIORAD, CA, USA). For all cytokines tested, any sample falling below the lowest concentration on the standard curve was assigned to a level of 0 ng/mL.

Statistical analyses

Statistical analyses were performed with SPSS statistical software, version 15.0 (SPSS, Chicago, IL). To analyze associations between discrete and categorical numerical variables, the χ² test and Fisher test were used. A comparison of the mean values of different groups was carried out with the Student unpaired t test, the Wilcoxon test, and the analysis of variance test. A forward stepwise regression logistic analysis was performed to find variables associated with graft rejection. Survival curves were calculated according to the Kaplan- Meier method, and differences between curves were evaluated with the log-rank test. A P value less than 0.05 was considered to be significant. We defined “graft rejection” as liver damage diagnosed by biopsy or that had good evolution with an increased immunosuppressant therapy. We only considered acute rejection episodes in this work.

The diagnosis of liver toxicity was made by excluding other potential causes, including infections, congestive heart failure, liver disease relapse or graft rejection, and was considered highly probable if the patients showed elevated liver enzymes (>10 fold increase in γ-glutamyl transferase ± aspartate aminotransferase ± alanine aminotransferase) without associated infections or without response to antirejection therapy.

High levels of donor hematopoietic chimerism were associated with non-rejection liver recipients

An informative polymorphism to differentiate recipient and donor was found in 74 of 76 cases (97.4%). DC was detected in 241 of the 468 samples (51.5%) with a median of 0.02% (range 0.0045- 175%). DC was expressed as a percentage of donor DNA in relation to total DNA in the post-transplant recipient samples. No difference in mean DC in peripheral blood was detected between the rejection and non-rejection group, when we compared mean DC of all patient samples (in log) (Figure 1A). Nevertheless, high levels of DC in serum samples were associated with non-rejection liver recipients (Figure 1B). Donor/recipient chimerism was studied along 30 months in peripheral blood and serum samples (Figures 1C and 1D). The analysis of posttransplant evolution by time intervals showed high DC during the first three months in the group without graft rejection in peripheral blood and serum samples (p=0.005 and p=0.016, respectively) (Figure 2). Higher DC levels were detected in serum samples than in peripheral blood samples (7.23% ± 24.86 vs a 1.77% ± 13.59; p=0.006) (Figures 2A and 2B).

Figure 1: Donor chimerism in peripheral blood and serum samples in liver transplant recipients.
Graph A and B show the donor chimerism (DC) mean in peripheral blood or serum samples, respectively, versus liver rejection (n=47) or non-rejection cases (n=27). C and D graphs show the stability of donor chimerism in peripheral blood or serum samples versus time after liver transplantation. The numbers indicating the outliers in the figures are the sample identifications.

Figure 2: Donor chimerism in serum and peripheral blood in time intervals during liver post-transplant.
Donor/recipient chimerism follow-up versus graft rejection: Graphic A: n=32 non-rejection; 10 rejection. Graphic B: n=14 non-rejection; 14 rejection. Graphic C: n=25 non-rejection; 11 rejection. Graphic D: n=21 non-rejection; 6 rejection. Graphic E: n=20 non-rejection; 5 rejection. Graphic F: n=35 non-rejection; 16 rejection. The number indicating the outliers in the figures are the sampleidenfications.

Chimerism levels were correlated with platelet count (r0.234, p<0.001); or inversely with leucocyte count (r-0.139; p-0.005) and lymphocyte count (r-0.188; p<0.001). We observed higher DC in female recipients and male donors than other combinations (p=0.003), and higher DC in RH+ recipients and RH- donors than other combinations (p<0.001). There were no differences in distribution depending on gender or blood group between recipients and donors. In the same way, significant differences were not detected in relation to split graft or nonheart- beating donor. Similar to bone marrow transplantation, DC level was correlated inversely with Mycofenolate level (r-0.173; p=0.022), but no correlations were found for TAC or CYA levels.

High levels of donor hematopoietic chimerism in serum samples were associated with liver disease relapse

No differences in levels of chimerism in peripheral blood were observed related to liver disease relapse. However higher levels of chimerism in serum samples were detected in the group which had liver disease relapse (p=0.018 in the second sample and p=0.008 in the third sample post-transplant) than the non-relapse group.

A CD56 Bright NK cell subset dominates the early posttransplant period following liver transplantation

Among liver recipients, median pre-transplant and one month post-transplant CD56 bright NK cells were 4.61% vs 15.70% (p=0.0029) (Figure 3). No differences were observed at other times or NK subsets. Only data from one pair of donor/recipient samples corresponding to a liver rejection case was available. CD56 dim NK percentage for this recipient was similar to non-rejection median (98.60% vs 87.89% vs) and CD56 bright NK was 1.51% (median 11.49%).

Figure 3: NK populations in liver recipients.
Phenotypic characterization of CD56+bright and CD56+dim NK cell subsets using flow cytometry in 11 pre-transplant and 11 post-transplant recipient samples. CD3- CD56+ NK cells were separated into two subsets, CD56+bright and CD56+dim based on the cell surface density of CD56. Y-line represents the mean of percentage of lymphocytes in the NK subsets (first column), or percentage of CD3-CD56+ NK cells in the NK CD56 dim and NK bright subsets (second and third columns), in peripheral blood of liver recipients. NK bright/dim ratio is shown in pre-transplant and at 1 month post-transplant recipientsamples (graph at rigth).

Disparities in both NK cell subsets were found when comparing liver recipient and donor percentages. Median CD56dim NK cells in recipients was 89.034% vs 56.86% in donors (p=0.009). Median CD56bright NK cells in recipients was 4.61% vs 2.94% in donors (p=0.015); Median NK bright/NK dim ratio was 0.0512 vs 0.17 in recipients and donors respectively (Figure 4).

Figure 4: NK populations in donors vs liver recipients. Phenotypic characterization of CD56+bright and CD56+dim NK cell subsets using flow cytometry in 11 recipients and 9 donor samples. NK bright/dim ratio is shown in donor samples and at 1 month post-transplant in recipient samples.

Impact of KIR-ligand mismatch on allograft outcome in liver transplantation

In the study of alloreactivity, a higher NK activity was shown in pre-transplant recipients than in post-transplant recipients or in donor samples (Figure 5). KIR-ligand mismatch/match was defined according to van Bergen et al. [27]. KIR ligand mismatch was detected in 12/22 cases (54.5%) and a tendency to association was observed between acute rejection and KIR ligand mismatch: patients with alloreactivity, 5 cases in the group with no rejection and 7 in the rejection group; patients without alloreactivity, 8 cases in the group with no rejection and 2 in the rejection group (p=0.069). We investigated the impact of the number of active or inhibitory KIR genes in recipients. The presence of KIR haplotype B (containing multiple activating KIR genes) has been reported to affect outcomes in hematopoietic stem cell transplantation [28,29]. But we did not observe influence of recipient and donor KIR genotypes on liver rejection.

Figure 5: Alloreactivity studies in donor and liver recipients. NK cytotoxicity at different effector-to target ratios (E/T ratios). Effector cells (NK cells) were incubated with BATDA labeled K562 target cells at different effector-to-target (E : T) ratios from 7 : 1, 3.5 : 1, and 1.75 : 1. Flow cytometry-based cytolysis of K562 target cells by isolated NK cells (

Discussion

Starzl [7] was the first to make a strong argument about allogeneic microchimerism, in which the donor passenger leukocytes that migrate widely into the recipient’s lymphoid tissues are essential for the maintenance of clonal exhaustion-deletion. This is induced by the initial flood of passenger leukocytes during the first few weeks after transplantation, and the survival of passenger leukocytes is associated with long-term acceptance of the graft.

We reported in a previous work [14] that stable levels of DC, in the absence of other major clinical events, may be a marker of transplantation tolerance, and may help to tailor immunosuppressive treatment in liver transplantation. We have confirmed, in this prospective work, the relevance of DC observed in the first ten post-transplantation months. However, other variables might influence the levels of DC, especially when they are determined in serum samples. High chimerism levels in serum samples in cases with liver disease relapse can be related to DNA released from the graft where the graft has an endothelial injury. In this sense, our DC results in peripheral blood would reflect more appropriately the positive effect on tolerance.

Natural killer (NK) cell function can be modulated by killer cell immunoglobulin-like recipients (KIR), which interact with human leukocyte antigen (HLA) class I molecules on target cells. KIRligand mismatching has been shown by van Bergen et al. [27] to be a significant risk factor for long-term graft loss in HLA-A, -B and -DR compatible kidney transplants. Nevertheless, Tran et al. [30] studied this finding, and performed genotyping on HLA-A, -B and -DR of 608 deceased-donor kidney graft recipients, and found no impact of KIR-ligand mismatch on allograft outcome in HLA-compatible kidney transplantation. Recently, Minguela et al. [31] studied 402 liver recipients and found that KIR gene-gene mismatch is associated with acute rejection and KIR2DS4+/C ligands also influence short-term graft survival. Our results support the findings that KIR mismatch has influence on acute rejection although the difference is not significant, probably because of the very small cohort in our study. Other authors [22] described that KIR genotype and KIR-HLA-C ligand compatibility play roles in the recurrence and progression of hepatitis C in liver transplant recipients but our results have not shown this.

The expansion of the cytokine-producing CD56 (bright) NK cell subset is a main feature of lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation (HSCT) [32]. We observed an increase of CD56(bright) NK cells during first post-transplant month compared to the pre-transplant period. Despite our cohort to study CD56 NK subtypes only included a graft rejection recipient, it should be noted that a clearly lower NKbright/NKdim ratio was obtained in this case.

We detected lower cytokine levels in pre-transplant recipient samples associated with liver toxicity (MIP1b) and liver disease relapse (TNFαlpha). These results have not been previously published. Papers with correlations between graft outcome and pre-transplant cytokine determinations are few in liver transplantation, but Friedman´s work [33] showed in multivariate analyses that patients experiencing early allograft dysfunction had lower pre-operative IL-6 and higher IL-2R levels.

Nader Najafian et al. published [34] a paper aimed at determining the utility of a noninvasive cytokine assay in screening of acute rejection and their analyses revealed a strong association between posttransplant IL-6 levels and acute rejection after multivariate adjustment for clinical characteristics (P<0.001) . Although six cytokines (IL-IB, IL6, TNF, IL4, GM-CSF and MCP-1) distinguished acute rejectors in the training cohort, logistic regression modeling identified one IL-6 as the best predictor. But we found no relation between post-transplant IL-6 levels and acute rejection cases although we observed lower OS with high IL6 levels. We detected lower post-transplant GMCSF levels to be associated with graft rejection. Nevertheless, lower IL17 (p=0.008) and TNF levels (p=0.009) and higher IL1β (p=0.010) and GMCSF levels (p=0.008) were associated with low RFS in the survival analysis. A possible origin for the high GMCSF secretion pointed at the increased CD56 Bright NK population [35]. Elevated GMCSF might in turn induce macrophage differentiation and as result an increased IL1β production. This hypothesis would imply an important role for CD56 Bright NK cells on graft rejection.

IL17 is a cytokine which acts as a potent mediator in delayed-type reactions, with a pro-inflammatory function and acts synergistically with TNF and interleukin-1. IL17, secreted by Th 17 cells, is a highly inflammatory cytokine with a robust effect on stromal cells in many tissues [36-38] and its expression is increased in bronchoalveolar lavages in patients with lung transplantation rejection. Hsieh et al. [39] reported that IL-17 could serve as a predictive parameter for borderline subclinical renal allograft rejection in the future. TNF alpha is an adipokine involved in systemic inflammation and is a member of a group of cytokines which stimulate the acute phase reaction. The ratio of IL10/TNFα expression in regulatory B cells may be a better indicator of regulatory function than IL10 expression alone for the prediction of immunologic human allograft injury [40]. Our results agree with previously published papers and also detected lower TNFα and IL17 levels associated with low RFS.

On the other hand, cytokine levels could be influenced by the particular immunosuppressant therapy. Patients on calcineurin inhibitors had impaired inflammatory cytokine production in response to TLR2, TLR4, and TLR7/8 stimulation compared with healthy controls [41]. In our work, the influence of immunosuppressive regimen (2 or 3 drugs vs 1 drug) on cytokine levels showed a tendency to decrease the level of IL4.

Gender donor/recipient mismatch was independently associated with the probability of graft rejection even when clinical and biological tolerance markers were considered. A higher risk of graft loss in male recipients after liver transplantation from female donors has been reported before by other authors [42]. Also male-to-female liver transplantations seem to present in some cases complications during surgery intervention with a negative impact in the patient outcome [43]. As Rustgy et al. remarked immunologic factors are influenced by gender; anyhow, additional studies are required to confirm this finding and to clearly uncover its causes. Although only gender donor/ recipient mismatch was associated with graft rejection in multivariate analysis, DC in peripheral blood/serum samples, KIR ligand mismatch and cytokine levels (TNFα, IL17, GMCSF, IL1β and IL6) should be incorporated into the evaluation of liver recipients in the screening of operational tolerance programs.

In conclusion, we have confirmed that high chimerism levels in peripheral blood during the first months after transplantation are related with a lower probability of rejection. A CD56 bright NK cell subset dominates the early post-transplant period following liver transplantation. A tendency to high frequency of graft rejection was observed in cases with KIR-ligand mismatches. Donors lacking C1ligands exhibited increased risk of acute rejection. Cytokine levels predict events in liver transplant recipients: low TNFα levels in pretransplant recipient samples were associated with liver disease relapse and low IL17 and TNFα levels and high GMCSF and IL1β levels are associated with low rejection free survival. Finally IL6 levels show an adverse impact on recipient overall survival.

Competing Interests

The authors declare that they have no competing interests.

Authors' Contributions

RA, EM and JML designed research, analyzed data, and wrote the paper; IR and SB analyzed the data; and SG, AP, JLV, MS, JAM, CL, and CJ performed the research. All authors read and approved the final manuscript.

Acknowledgements

The work was supported by Fundación Mutua Madrileña grant 2011/0083.

References

1. Bishop GA, Ierino FL, Sharland AF, Hall BM, Alexander SI, et al. (2011) Approaching the promise of operational tolerance in clinical transplantation. Transplantation 91: 1065-1074.
2. Penninga L, Wettergren A, Chan AW, Steinbruchel DA (2012) Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Cochrane Database Syst Rev 3: CD008852.
3. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, et al. (1994) Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58: 170-178.
4. Vercauteren SB, Bosmans JL, Elseviers MM, Verpooten GA (1998) A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int 54: 536-545.
5. Bishop GA, McCaughan GW (2001) Immune activation is required for the induction of liver allograft tolerance: implications for immunosuppressive therapy. Liver Transpl 7: 161-172.
6. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, et al. (1992) Cell migration, chimerism, and graft acceptance. Lancet 339: 1579-1582.
7. Starzl TE (2008) Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med 358: 407-411.
8. Starzl TE, Lakkis FG (2006) The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology 43: S151-163.
9. Starzl TE, Zinkernagel RM (1998) Antigen localization and migration in immunity and tolerance. N Engl J Med 339: 1905-1913.
10. Starzl TE, Zinkernagel RM (2001) Transplantation tolerance from a historical perspective. Nat Rev Immunol 1: 233-239.
11. Starzl TE (2007) Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res 38: 6-41.
12. Starzl TE, Murase N, Demetris AJ, Trucco M, Abu-Elmagd K, et al. (2004) Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation 77: 926-929.
13. Ayala R, Grande S, Albizua E, Crooke A, Meneu JC, et al. (2009) Long-term follow-up of donor chimerism and tolerance after human liver transplantation. Liver Transpl 15: 581-591.
14. Mazariegos GV, Zahorchak AF, Reyes J, Ostrowski L, Flynn B, et al. (2003) Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 3: 689-696.
15. Levitsky J1 (2011) Operational tolerance: past lessons and future prospects. Liver Transpl 17: 222-232.
16. Li Koshiba YT, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, et al. (2004) Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 4: 2118-225.
17. Li Y, Zhao X, Cheng D, Haga H, Tsuruyama T, et al. (2008) The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 86: 1837-1843.
18. Velardi A (2008) Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol 20: 581-587.
19. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, et al. (2005) Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174: 6540-6545.
20. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
21. de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, et al. (2009) Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl15:390-399.
22. Lopez-Alvarez MR, Moya-Quiles MR, Minguela A, Gil J, Miras M, et al. (2009) HLA-C matching and liver transplants: donor-recipient genotypes influence early outcome and CD8+KIR2D+ T-cells recuperation. Transplantation 88:S54-61.
23. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, et al. (2002) Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood99:4618-4625.
24. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
25. Pérez-Martínez A, González-Vicent M, Valentín J, Aleo E, Lassaletta A, et al. (2012) Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplant 47: 1419-1427.
26. van Bergen J, Thompson A, Haasnoot GW, Roodnat JI, de Fijter JW, et al. (2011) KIR-ligand mismatches are associated with reduced long-term graft survival in HLA-compatible kidney transplantation. Am J Transplant 11: 1959-1964.
27. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, et al. (2009) Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood13:726-732.
28. Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, et al. (2011) Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 25: 1657-1661.
29. Tran TH, Unterrainer C, Fiedler G, Döhler B, Scherer S, et al. (2013) No impact of KIR-ligand mismatch on allograft outcome in HLA-compatible kidney transplantation. Am J Transplant 13: 1063-1068.
30. Legaz I, Lopez-Alvarez MR, Campillo JA, Moya-Quiles MR, Bolarin JM, et al. (2013) KIR gene mismatching and KIR/C ligands in liver transplantation: consequences for short-term liver allograft injury. Transplantation 95:1037-1044.
31. Dulphy N, Haas P, Busson M, Belhadj S, Peffault de Latour R, et al. (2008) An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol 181:2227-2237.
32. Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, et al. (2012) Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl 18:166-176.
33. De Serres SA, Mfarrej BG, Grafals M, Riella LV, Magee CN, et al. (2012) Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients. Clin J Am Soc Nephrol 7: 1018-1025.
34. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, et al. (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97: 3146-3151.
35. Chen H, Wang W, Xie H, Xu X, Wu J, et al. (2009) A pathogenic role of IL- 17 at the early stage of corneal allograft rejection. Transpl Immunol 21: 155-161.
36. Tesmer LA, Lundy SK, Sarkar S, Fox DA (2008) Th17 cells in human disease. Immunol Rev 223: 87-113.
37. Vanaudenaerde BM, Dupont LJ, Wuyts WA, Verbeken EK, Meyts I, et al. (2006) The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 27: 779-787.
38. Hsieh HG, Loong CC, Lui WY, Chen A, Lin CY (2001) IL-17 expression as a possible predictive parameter for subclinical renal allograft rejection. Transpl Int 14:287-298.
39. Cherukuri A, Rothstein DM, Clark B, Carter CR, Davison A, et al. (2014) Immunologic Human Renal Allograft Injury Associates with an Altered IL-10/TNF-alpha Expression Ratio in Regulatory B Cells. J Am Soc Nephrol 25: 1575-1585.
40. Howell J, Sawhney R, Testro A, Skinner N, Gow P, et al. (2013) Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation. Liver Transpl 19: 1099-1107.
41. Rustgi VK, Marino G, Halpern MT, Johnson LB, Umana WO, et al. (2002) Role of gender and race mismatch and graft failure in patients undergoing liver transplantation. Liver Transpl 8: 514-518.
42. Grat M, Lewandowski Z, Patkowski W, Wronka KM, Grat K, et al. (2015) Relevance of male-to-female sex mismatch in liver transplantation for primary biliary cirrhosis. Ann Transplant 20: 116-123.

Citation: Ayala R, Rapado I, Perez A, Grande S, Arenas A, et al. (2016) Donor Chimerism, Kir Ligand Mismatch and Cytokine Levels (Tnfα, Il17, Gmcsf, Il1β) and their Association with Graft Rejection in Liver Transplant Recipients. J Clin Cell Immunol 7:407.

Copyright: © 2016 Ayala R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.